Seminars in Hematology
Volume 43, Issue 1 , Pages 53-61 , January 2006

Graft-Versus-Host Disease and Graft-Versus-Leukemia After Donor Leukocyte Infusion

  • David Porter

      Affiliations

    • Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, PA.
    • ,
  • John E. Levine

      Affiliations

    • Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI.
    • Corresponding Author InformationAddress correspondence to John E. Levine, MD, Associate Professor of Pediatrics, University of Michigan Medical School, 1500 E Medical Center Dr, B1-207 CCGC, Ann Arbor, MI 48109-0914.

References 

  1. Odom L , August C , Githens J . Remission of relapsed leukaemia during a graft-versus-host reaction. A “graft-versus-leukaemia” reaction in man? . Lancet . 1978;2:537–540
  2. Sullivan K , Weiden P , Storb R . Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia . Blood . 1989;73:1720–1728
  3. Horowitz MM , Gale RP , Sondel PM , et al.   Graft-verus-leukemia reactions after bone marrow transplantation . Blood . 1990;75:555–562
  4. Gale R , Horowitz M , Ash R . Identical-twin bone marrow transplants for leukemia . Ann Intern Med . 1994;120:646–652
  5. Weiden PL , Flournoy N , Sanders JE , Sullivan KM , Thomas ED , et al.   Antileukemic effect of chronic graft-versus-host disease (Contribution to improved survival after allogeneic marrow transplantation) . N Engl J Med . 1981;304:1529–1533
  6. Goldman JM , Gale RP , Horowitz MM , Biggs JC , Champlin RE , Gluckman E , et al.   Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion . Ann Intern Med . 1988;108:806–814
  7. Kolb H-J , Schattenberg A , Goldman JM , Hertenstein B , Jacobsen N , Arcese W , et al.   Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients . Blood . 1995;86:2041–2050
  8. Collins RH , Shpilberg O , Drobyski WR , Porter DL , Giralt S , Champlin R , et al.   Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation . J Clin Oncol . 1997;15:433–444
  9. Porter D , Roth M , McGarigle C , Ferrara JL , Antin JH , et al.   Induction of graft versus host disease as immunotherapy for relapsed chronic myeloid leukemia . N Engl J Med . 1994;330:100–106
  10. Lokhorst HM , Schattenberg A , Cornelissen JJ , van Oers MH , Fibbe W , Russell I , et al.   Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation (Predictive factors for response and long-term outcome) . J Clin Oncol . 2000;18:3031–3037
  11. Collins RH , Goldstein S , Giralt S , Levine J , Porter D , Drobyski W , et al.   Donor leukocyte infusions in acute lymphocytic leukemia . Bone Marrow Transplant . 2000;26:511–516
  12. Levine JE , Braun T , Penza SL , Beatty P , Cornetta K , Martino R , et al.   Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation . J Clin Oncol . 2002;20:405–412
  13. Kolb H , Mittermuller J , Clemm C , Holler E , Ledderose G , Brehm G , et al.   Donor leukocyte transfusions for treatment of recurrent chronic myelogenousleukemia in marrow transplant patients . Blood . 1990;76:2462–2465
  14. Drobyski WR , Keever CA , Roth MS , Koethe S , Hanson G , McFadden P , et al.   Salvage immunotherapy using donor leukocyte transfusions as treatment for relapse chronic myelogenous leukemia after allogeneic bone marrow transplantation (Efficacy and toxicity of a defined T-cell dose) . Blood . 1993;82:2310–2318
  15. Helg C , Roux E , Beris P , Cabrol C , Wacker P , Darbellay R , et al.   Adoptive immunotherapy for recurrent CML after HSCT . Bone Marrow Transplant . 1993;12:125–129
  16. Hertenstein B , Wiesneth M , Novotny J , Bunjes D , Stefanic M , Heinze B , et al.   Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation . Transplantation . 1993;56:1114–1118
  17. Roth MS , Antin JH , Bingham EL , Ginsburg D . Detection of Philadelphia chromosome-positive cells by the polymerase chain reaction following boe marrow transplant for chronic myelogenous leukemia . Blood . 1989;74:882–885
  18. Porter D , Antin J . Graft-versus-leukemia effect of allogeneic bone marrow transplantation and donor mononuclear cell infusions . In:  Winter J editors. Blood Stem Cell Transplantation . Norwell, MA: Kluwer; 1997;p. 57–86
  19. Dazzi F , Szydlo RM , Cross NC , Craddock C , Kaeda J , Kanfer E , et al.   Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia . Blood . 2000;96:2712–2716
  20. Porter DL , Connors JM , Van Deerlin VM , Duffy KM , McGarigle C , Saidman SL , et al.   Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies . J Clin Oncol . 1999;17:1234–1243
  21. Kolb HJ . Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. Immunology and Chronic Leukemia Working Parties . Vox Sang . 1998;74(suppl 2):321–329
  22. Mandanas RA , Saez RA , Selby GB , Confer DL . G-CSF-mobilized donor leukocyte infusions as immunotherapy in acute leukemia relapsing after allogeneic marrow transplantation . J Hematother . 1998;7:449–456
  23. Singhal S , Powles R , Kulkarni S , Treleaven J , Saso R , Mehta J , et al.   Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation (The inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse) . Leuk Lymphoma . 1999;32:505–512
  24. Akpek G , Zahurak ML , Piantadosi S , Margolis J , Doherty J , Davidson R , et al.   Development of a prognostic model for grading chronic graft-versus-host disease . Blood . 2001;97:1219–1226
  25. Tricot G , Vesole DH , Jagannath S , Hilton J , Munshi N , Barlogie B . Graft-versus-myeloma effect (Proof of principle) . Blood . 1996;87:1196–1198
  26. Lokhorst HM , Schattenberg A , Cornelissen JJ , Thomas LL , Verdonck LF . Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation . Blood . 1997;90:4206–4211
  27. Salama M , Nevill T , Marcellus D , Parker P , Johnson M , Kirk A , et al.   Donor leukocyte infusions for multiple myeloma . Bone Marrow Transplant . 2000;26:1179–1184
  28. Alyea E , Weller E , Schlossman R , Canning C , Webb I , Doss D , et al.   T-cell–depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma (Induction of graft-versus-myeloma effect) . Blood . 2001;98:934–939
  29. Badros A , Barlogie B , Morris C , Desikan R , Martin SR , Munshi N , et al.   High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions . Blood . 2001;97:2574–2579
  30. Ratanatharathorn V , Uberti J , Karanes C , Abella E , Lum LG , Momin F , et al.   Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin’s lymphoma . Blood . 1994;84:1050–1055
  31. Jones RJ , Ambinder RF , Piantadosi S , Santos GW . Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation . Blood . 1991;77:649–653
  32. Bernard M , Dauriac C , Drenou B , Leberre C , Branger B , Fauchet R , et al.   Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin’s lymphoma . Bone Marrow Transplant . 1999;23:329–333
  33. Mandigers CM , Meijerink JP , Raemaekers JM , Schattenberg AV , Mensink EJ , et al.   Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18) . Lancet . 1998;352:1522–1523
  34. Robinson SP , Goldstone AH , Mackinnon S , Carella A , Russell N , de Elvira CR , et al.   Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation (An analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation) . Blood . 2002;100:4310–4316
  35. Porter DL , Stadtmauer EA , Lazarus HM . ’GVHD’: Graft-versus-host disease or graft-versus-Hodgkin’s disease? An old acronym with new meaning . Bone Marrow Transplant . 2003;31:739–746
  36. Flowers ME , Leisenring W , Beach K , Riddell S , Radich JP , Higano CS , et al.   Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation . Biol Blood Marrow Transplant . 2000;6:321–326
  37. Giralt S , Hester J , Huh Y , Hirsch-Ginsberg C , Rondon G , Seong D , et al.   CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation . Blood . 1995;86:4337–4343
  38. Mehta J , Powles R , Treleaven J , Horton C , Meller S , Pinkerton CR , et al.   Outcome of acute leukemia relapsing after bone marrow transplantation (Utility of second transplants and adoptive immunotherapy) . Bone Marrow Transplant . 1997;19:709–719
  39. Leis J , Porter DL . Unrelated donor leukocyte infusions to treat relapse after unrelated donor bone marrow transplantation . Leuk Lymphoma . 2002;43:9–17
  40. Porter DL , Collins RH , Hardy C , Kernan NA , Drobyskin WR , Giralt S , et al.   Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions . Blood . 2000;95:1214–1221
  41. Mackinnon S , Papadopoulos E , Carabasi M , Reich L , Collins NH , Boulad F , et al.   Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation (Separation of graft-versus-leukemia responses from graft-versus-host disease) . Blood . 1995;86:1261–1268
  42. Elfenbein GG-PJ , Weiner R , Goedert T , Gross S . Consequences of no prophylaxis for acute graft-versus-host disease after HLA-identical bone marrow transplantation . Blood . 1987;70(suppl 1):305a
  43. Sullivan K , Schulman H . Chronic graft-versus-host disease, obliterative bronchiolitis, and graft-versus-leukemia effect (Case histories) . Transplant Proc . 1989;21:51–62
  44. Antin JH , Ferrara JLM . Cytokine dysregulation and acute graft-versus-host disease . Blood . 1992;80:2964–2968
  45. Porter D , Roth M , McGarigle C , et al.   Induction of graft-vs-leukemia (GVL) reaction as therapy for relapsed leukemia after allogeneic bone marrow transplantation (HSCT) . J Cell Biochem . 1994;18B:94a
  46. Ratanatharathorn V , Nash RA , Przepiorka D , Devine SM , Klein JL , Weisdorf D , et al.   Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation . Blood . 1998;92:2303–2314
  47. Nash RA , Pepe MS , Storb R , Longton G , Pettinger M , Anasetti C , et al.   Acute graft-versus-host disease analysis of risk factors after allogeneic marrow transpantation and prophylaxis with cyclosporine and methotrexate . Blood . 1992;80:1838–1845
  48. Levine JE , Uberti JP , Ayash L , Reynolds C , Ferrara JL , Silver SM , et al.   Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy . Biol Blood Marrow Transplant . 2003;9:189–197
  49. Akpek G , Boitnott JK , Lee LA , Hallick JP , Torbenson M , Jacobsohn DA . Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion . Blood . 2002;100:3903–3907
  50. Marks DI , Lush R , Cavenagh J , Milligan DW , Schey S , Parker A , et al.   The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation . Blood . 2002;100:3108–3114
  51. Alyea EP , Soiffer RJ , Canning C , Neuberg D , Schlossman R , Pickett C , et al.   Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant . Blood . 1998;91:3671–3680
  52. Bethge WA , Hegenbart U , Stuart MJ , Storer BE , Maris MB , Flowers ME , et al.   Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning . Blood . 2004;103:790–795
  53. Dey BR , McAfee S , Sackstein R , Colby C , Saidman S , Weymouth D , et al.   Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation . Biol Blood Marrow Transplant . 2001;7:604–612
  54. Guglielmi C , Arcese W , Dazzi F , Brand R , Bunjes D , Verdonck LF , et al.   Donor lymphocyte infusion for relapsed chronic myelogenous leukemia (Prognostic relevance of the initial cell dose) . Blood . 2002;100:397–405
  55. Barrett AJ , Malkovska V . Graft-versus-leukemia (Understanding and using the alloimmune response to treat haematological malignancies) . Br J Haematol . 1996;93:754–761
  56. Johnson BD , Drobisky WD , Truitt RL . Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an anti-leukemia reaction without graft-versus-host disease . Bone Marrow Transplant . 1993;11:329–336
  57. Weiden P , Storb R , Tsoi M . Infusion of donor lymphocytes into stable canine radiation chimeras (Implications for mechanism of transplantation tolerance) . J Immunol . 1978;116:1212–1219
  58. Kolb HJ , Gunther W , Schumm M , Holler E , Wilmans W , Thierfelder S . Adoptive immunotherapy in canine chimeras . Transplantation . 1997;63:430–436
  59. Shimoni A , Gajewski JA , Donato M , Martin T , O’Brien S , Talpaz M , et al.   Long-term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation . Biol Blood Marrow Transplant . 2001;7:568–575
  60. Waller EK , Ship AM , Mittelstaedt S , Murray TW , Carter R , Kakhniashvili I , et al.   Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease . Blood . 1999;94:3222–3233
  61. Truitt RL , Johnson BD , Hanke C , Talib S , Hearst JE . Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation . J Immunol . 1999;163:5145–5156
  62. Servida P , Bordignon C . Gene therapy and apheresis . Int J Artif Organs . 1993;16(suppl 5):116–118
  63. Bonini C , Ferrari G , Verzeletti S , Servida P , Zappone E , Ruggieri L , et al.   HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia . Science . 1997;276:1719–1724
  64. Falkenburg JH , Wafelman AR , Joosten P , Smit WM , van Bergen CA , Bongaerts R , et al.   Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes . Blood . 1999;94:1201–1208
  65. Barnes D , Loutit J . Treatment of murine leukaemia with x-rays and homologous bone marrow . Br J Haematol . 1957;3:241–252
  66. Mathe G , Amiel JL , Schwarzenberg L , Cattan L , Schneider M . Adoptive immunotherapy of acute leukemia (experimental and clinical results) . Cancer Res . 1965;25:1525–1531
  67. Shiobara S , Nakao S , Ueda M , Yamazaki H , Takahashi S , Asano S , et al.   Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation (Indications and dose escalation) . Ther Apher . 2001;5:40–45
  68. van Rhee F , Savage D , Blackwell J , Orchard K , Dazzi F , Lin F , et al.   Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant (Equal efficacy of lymphocytes from sibling and matched unrelated donors) . Bone Marrow Transplant . 1998;21:1055–1061
  69. Lokhorst HM , Wu K , Verdonck LF , Laterveer LL , van de Donk NW , van Oers MH , et al.   The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma . Blood . 2004;103:4362–4364

PII: S0037-1963(05)00171-X

doi: 10.1053/j.seminhematol.2005.09.005

Seminars in Hematology
Volume 43, Issue 1 , Pages 53-61 , January 2006

Article Tools

* Image Usage & Resolution